Clinical assessment of treatments for prolonged bleeding in users of Norplant implants - PubMed (original) (raw)
Clinical Trial
Clinical assessment of treatments for prolonged bleeding in users of Norplant implants
S Díaz et al. Contraception. 1990 Jul.
Abstract
The effectiveness of three drugs in controlling prolonged bleeding in the first year of NORPLANT implants use was tested. The drugs were levonorgestrel (L-Ng, 0.03 mg twice a day for 20 days), ethinylestradiol (EE, 0.05 mg per day for 20 days) and ibuprofen (Ib, 800 mg three times a day for 5 days) and were given orally. A control group received a placebo (PL, one pill of lactose for 20 days). Treatment should start each time a woman experienced eight consecutive days of bleeding or spotting. The 183 volunteers were not aware of the drug administered. A daily record of bleeding and spotting and of treatment intake was maintained. One-hundred-forty women completed the study period; 60 never used the prescribed treatment. Women treated with the three test drugs had significantly fewer bleeding and spotting days during the treated month and also throughout the study year than women using the placebo. The mean number of bleeding plus spotting days per actually treated subject in the first year was 77, 94, 101 and 129 days for the EE, Ib, L-Ng and PL groups, respectively. The administration of EE might help in the management of prolonged bleeding during the first year of NORPLANT implants use.
Similar articles
- Oestrogen treatment for increased bleeding in Norplant users: preliminary results.
Witjaksono J, Lau TM, Affandi B, Rogers PA. Witjaksono J, et al. Hum Reprod. 1996 Oct;11 Suppl 2:109-14. doi: 10.1093/humrep/11.suppl_2.109. Hum Reprod. 1996. PMID: 8982752 Clinical Trial. - Hormonal treatment for bleeding irregularities in Norplant implant users.
Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Alvarez-Sanchez F, et al. Am J Obstet Gynecol. 1996 Mar;174(3):919-22. doi: 10.1016/s0002-9378(96)70326-5. Am J Obstet Gynecol. 1996. PMID: 8633669 Clinical Trial. - Management of irregular uterine bleeding and spotting associated with Norplant.
Archer DF, Philput CA, Weber ME. Archer DF, et al. Hum Reprod. 1996 Oct;11 Suppl 2:24-30. doi: 10.1093/humrep/11.suppl_2.24. Hum Reprod. 1996. PMID: 8982742 Clinical Trial. - Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
Abdel-Aleem H, d'Arcangues C, Vogelsong K, Gülmezoglu AM. Abdel-Aleem H, et al. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003449. doi: 10.1002/14651858.CD003449.pub2. Cochrane Database Syst Rev. 2007. PMID: 17443526 Updated. Review. - Norplant: subdermal implant system for long-term contraception.
Shoupe D, Mishell DR. Shoupe D, et al. Am J Obstet Gynecol. 1989 May;160(5 Pt 2):1286-92. doi: 10.1016/s0002-9378(89)80014-6. Am J Obstet Gynecol. 1989. PMID: 2497646 Review.
Cited by
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024.
Curtis KM, Nguyen AT, Tepper NK, Zapata LB, Snyder EM, Hatfield-Timajchy K, Kortsmit K, Cohen MA, Whiteman MK; Contributors. Curtis KM, et al. MMWR Recomm Rep. 2024 Aug 8;73(3):1-77. doi: 10.15585/mmwr.rr7303a1. MMWR Recomm Rep. 2024. PMID: 39106301 Free PMC article. - Endometrial histology of Depomedroxyprogesterone acetate users: a pilot study.
Thurman AR, Soper DE. Thurman AR, et al. Infect Dis Obstet Gynecol. 2006;2006:69402. doi: 10.1155/IDOG/2006/69402. Infect Dis Obstet Gynecol. 2006. PMID: 17093355 Free PMC article. - Levonorgestrel subdermal implants. Contraception on trial.
Frank ML, DiMaria C. Frank ML, et al. Drug Saf. 1997 Dec;17(6):360-8. doi: 10.2165/00002018-199717060-00002. Drug Saf. 1997. PMID: 9429835 Review. - Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.
Sivin I. Sivin I. Drug Saf. 2003;26(5):303-35. doi: 10.2165/00002018-200326050-00002. Drug Saf. 2003. PMID: 12650633 Review. - Iatrogenic unscheduled (breakthrough) endometrial bleeding.
Hickey M, Fraser IS. Hickey M, et al. Rev Endocr Metab Disord. 2012 Dec;13(4):301-8. doi: 10.1007/s11154-012-9227-3. Rev Endocr Metab Disord. 2012. PMID: 23224719 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical